Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

LRRK2 activation in idiopathic Parkinson's disease.

Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, Zharikov A, Van Laar A, Stepan AF, Lanz TA, Kofler JK, Burton EA, Alessi DR, Hastings TG, Greenamyre JT.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaar5429. doi: 10.1126/scitranslmed.aar5429.

PMID:
30045977
2.

Unabated occupational risk in a patient with rheumatoid pulmonary fibrosis.

Holden VK, Kligerman SJ, Hastings TG, Hines SE.

Occup Med (Lond). 2017 Jun 1;67(4):311-313. doi: 10.1093/occmed/kqx030.

PMID:
28339739
3.

α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.

Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, Hastings TG, Greenamyre JT.

Sci Transl Med. 2016 Jun 8;8(342):342ra78. doi: 10.1126/scitranslmed.aaf3634.

4.

Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone.

Van Laar VS, Berman SB, Hastings TG.

Neurobiol Dis. 2016 Jul;91:247-61. doi: 10.1016/j.nbd.2016.03.015. Epub 2016 Mar 19.

5.

shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.

Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT, Burton EA.

J Clin Invest. 2015 Jul 1;125(7):2721-35. doi: 10.1172/JCI64502. Epub 2015 Jun 15.

6.

Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4.

Hauser DN, Dukes AA, Mortimer AD, Hastings TG.

Free Radic Biol Med. 2013 Dec;65:419-427. doi: 10.1016/j.freeradbiomed.2013.06.030. Epub 2013 Jun 28.

7.

Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.

Hauser DN, Hastings TG.

Neurobiol Dis. 2013 Mar;51:35-42. doi: 10.1016/j.nbd.2012.10.011. Epub 2012 Oct 12. Review.

8.

The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease.

Hastings TG.

J Bioenerg Biomembr. 2009 Dec;41(6):469-72. doi: 10.1007/s10863-009-9257-z.

PMID:
19967436
9.

A comparison of Zn2+- and Ca2+-triggered depolarization of liver mitochondria reveals no evidence of Zn2+-induced permeability transition.

Devinney MJ, Malaiyandi LM, Vergun O, DeFranco DB, Hastings TG, Dineley KE.

Cell Calcium. 2009 May;45(5):447-55. doi: 10.1016/j.ceca.2009.03.002. Epub 2009 Apr 5.

10.

Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells.

Van Laar VS, Mishizen AJ, Cascio M, Hastings TG.

Neurobiol Dis. 2009 Jun;34(3):487-500. doi: 10.1016/j.nbd.2009.03.004. Epub 2009 Mar 28.

11.

Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine.

Dukes AA, Van Laar VS, Cascio M, Hastings TG.

J Neurochem. 2008 Jul;106(1):333-46. doi: 10.1111/j.1471-4159.2008.05392.x. Epub 2008 Jul 1.

12.

Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease.

Van Laar VS, Dukes AA, Cascio M, Hastings TG.

Neurobiol Dis. 2008 Mar;29(3):477-89. doi: 10.1016/j.nbd.2007.11.007. Epub 2007 Nov 28.

13.

Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice.

Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X.

J Neurosci. 2008 Jan 9;28(2):425-33. doi: 10.1523/JNEUROSCI.3602-07.2008.

14.

A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation.

Venneti S, Lopresti BJ, Wang G, Slagel SL, Mason NS, Mathis CA, Fischer ML, Larsen NJ, Mortimer AD, Hastings TG, Smith AD, Zigmond MJ, Suhara T, Higuchi M, Wiley CA.

J Neurochem. 2007 Sep;102(6):2118-2131. doi: 10.1111/j.1471-4159.2007.04690.x. Epub 2007 Jun 7.

15.

Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells.

Tehranian R, Montoya SE, Van Laar AD, Hastings TG, Perez RG.

J Neurochem. 2006 Nov;99(4):1188-96. Epub 2006 Sep 18.

16.

Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease.

Liang Q, Smith AD, Pan S, Tyurin VA, Kagan VE, Hastings TG, Schor NF.

Biochem Pharmacol. 2005 Nov 1;70(9):1371-81.

PMID:
16144694
17.

The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells.

Dukes AA, Korwek KM, Hastings TG.

Antioxid Redox Signal. 2005 May-Jun;7(5-6):630-8.

PMID:
15890007
18.

Could a loss of alpha-synuclein function put dopaminergic neurons at risk?

Perez RG, Hastings TG.

J Neurochem. 2004 Jun;89(6):1318-24. Review.

19.

Neuroproteomics: expression profiling of the brain's proteomes in health and disease.

Kim SI, Voshol H, van Oostrum J, Hastings TG, Cascio M, Glucksman MJ.

Neurochem Res. 2004 Jun;29(6):1317-31. Review.

PMID:
15176488
20.

Biomedicine. Parkinson's--divergent causes, convergent mechanisms.

Greenamyre JT, Hastings TG.

Science. 2004 May 21;304(5674):1120-2. No abstract available.

PMID:
15155938
21.

Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity.

LaVoie MJ, Card JP, Hastings TG.

Exp Neurol. 2004 May;187(1):47-57.

PMID:
15081587
22.

Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.

Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D.

J Neurosci. 2002 Oct 15;22(20):8951-60.

23.

Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?

Zigmond MJ, Hastings TG, Perez RG.

Parkinsonism Relat Disord. 2002 Sep;8(6):389-93. Review.

PMID:
12217625
24.
26.
28.

Cytotoxic and genotoxic potential of dopamine.

Stokes AH, Hastings TG, Vrana KE.

J Neurosci Res. 1999 Mar 15;55(6):659-65. Review.

PMID:
10220107
30.

Role of endogenous glutathione in the oxidation of dopamine.

Rabinovic AD, Hastings TG.

J Neurochem. 1998 Nov;71(5):2071-8.

31.

Neurochemical responses to lesions of dopaminergic neurons: implications for compensation and neuropathology.

Zigmond MJ, Hastings TG.

Adv Pharmacol. 1998;42:788-92. No abstract available.

PMID:
9328016
32.
33.

Characterization of hydrogen peroxide toxicity in cultured rat forebrain neurons.

Hoyt KR, Gallagher AJ, Hastings TG, Reynolds IJ.

Neurochem Res. 1997 Mar;22(3):333-40.

PMID:
9051670
35.

Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites.

Hastings TG, Zigmond MJ.

J Neural Transm Suppl. 1997;49:103-10. Review.

PMID:
9266419
36.

Modification of dopamine transporter function: effect of reactive oxygen species and dopamine.

Berman SB, Zigmond MJ, Hastings TG.

J Neurochem. 1996 Aug;67(2):593-600.

PMID:
8764584
37.

Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

Hastings TG, Lewis DA, Zigmond MJ.

Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1956-61.

38.

Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease.

Hastings TG, Lewis DA, Zigmond MJ.

Adv Exp Med Biol. 1996;387:97-106. No abstract available.

PMID:
8794199
39.
40.

Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine.

Giovanni A, Liang LP, Hastings TG, Zigmond MJ.

J Neurochem. 1995 Apr;64(4):1819-25.

PMID:
7891110
41.

Enzymatic oxidation of dopamine: the role of prostaglandin H synthase.

Hastings TG.

J Neurochem. 1995 Feb;64(2):919-24.

PMID:
7830086
43.

Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.

Zigmond MJ, Hastings TG, Abercrombie ED.

Ann N Y Acad Sci. 1992 May 11;648:71-86. Review. No abstract available.

PMID:
1637074
44.

Identification of the phosphoserine residue in histone H1 phosphorylated by protein kinase C.

Jakes S, Hastings TG, Reimann EM, Schlender KK.

FEBS Lett. 1988 Jul 4;234(1):31-4.

46.

Identification of a ternary complex between cAMP and a trimeric form of cAMP-dependent protein kinase.

Connelly PA, Hastings TG, Reimann EM.

J Biol Chem. 1986 Feb 15;261(5):2325-30.

Supplemental Content

Loading ...
Support Center